Biocryst Pharmaceuticals Inc valuation and forecast
Explore the models for Biocryst Pharmaceuticals Inc, adjust their assumptions and compare your own valuation with the platform's.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: after-tax interest is 63% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.
Price vs value
Under review: after-tax interest is 63% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy. We'll show the comparison once resolved.
Analyst recommendations
Monthly trend
- Oct 202611
- Sep 202611
- Aug 202611
- Jul 202611
Counts of recommendations published by analysts covering Biocryst Pharmaceuticals Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.
Price history
Loading chart…
Third-party market data · may be delayed
The assumptions
- Free cash flow (TTM, FY2026 Q2)
- $373M
- Less stock-based pay
- $73.1M
- Cash flow we value
- $154M
- Growth, years 1–5 (base)
- %
- Then fading to
- 2.5%
- Discount rate
- 8.5%
- Net cash added
- -$42.8M
- Diluted shares
- 255M
What would move the value
- Growth 5 points lower
- −24%
- Growth 5 points higher
- +30%
- Free-cash-flow margin 1 point lower
- −2%
- Discount rate 1 point higher
- −16%
Change in our model value when one input moves, all else equal.
BCRX valuation questions
- How does Fundamentalytics value Biocryst Pharmaceuticals Inc?
- We use the models that fit Biocryst Pharmaceuticals Inc's business and available financial data: cash-flow model (dcf). Each model has its own assumptions and data requirements. The calculator explains which models are available and lets you adjust their inputs.
Data: SEC EDGAR filings, retrieved October 29, 2026. Method: how we value companies. Disclosures: research and recommendations disclosure. Back to Biocryst Pharmaceuticals Inc.